pazopanib zentiva
zentiva k.s. - pazopanibas - plėvele dengtos tabletės - 200 mg - pazopanib
pazopanib zentiva
zentiva k.s. - pazopanibas - plėvele dengtos tabletės - 400 mg - pazopanib
axitinib stada
stada arzneimittel ag - aksitinibas - plėvele dengtos tabletės - 1 mg - axitinib
axitinib stada
stada arzneimittel ag - aksitinibas - plėvele dengtos tabletės - 3 mg - axitinib
axitinib stada
stada arzneimittel ag - aksitinibas - plėvele dengtos tabletės - 5 mg - axitinib
axitinib stada
stada arzneimittel ag - aksitinibas - plėvele dengtos tabletės - 7 mg - axitinib
deltyba
otsuka novel products gmbh - delamanid - tuberkuliozė, atspari daugeliui vaistinių preparatų - antimikobakterijos - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 ir 5. reikėtų atsižvelgti į oficialius nurodymus, kaip tinkamai naudoti antibakterinių veiksnių.
xeljanz
pfizer europe ma eeig - tofacitinib - artritas, reumatas - imunosupresantai - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ir 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.
gefitinib teva
teva b.v. - gefitinibas - plėvele dengtos tabletės - 250 mg - gefitinib
dasatinib krka
krka, d.d., novo mesto - dazatinibas - plėvele dengtos tabletės - 20 mg - dasatinib